Thinning revenues: inside the $14bn Eliquis patent cliff
Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent…
Eliquis proves safer than Xarelto for patients with deep blood clots
March 13 (Reuters) – A trial directly comparing Eliquis and Xarelto – two commonly used blood-thinning drugs from…